CoChat

Cortexolone 17α-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0·05% cream: Cortexolone 17α-propionate in acne vulgaris

Trifu, V., Tiplica, G.-S., Naumescu, E., Zalupca, L., Moro, L., Celasco, G. · 2011 · British Journal of Dermatology
Cited by 66

The DOI matches its Crossref record.

Abstract

BACKGROUND: Acne vulgaris is a disorder of the pilosebaceous unit in which the androgens contribute to its onset and persistence. The use of antiandrogens is therefore potentially effective; however, antiandrogens for topical use are not available on the market. Cortexolone 17α-propionate (CB-03-01; Cosmo S.p.A, Lainate, Italy) is a new potent topical antiandrogen potentially useful in acne vulgaris. OBJECTIVES: To evaluate the safety and the topical efficacy of CB-03-01 1% cream in acne vulgaris as compared with placebo and with tretinoin 0·05% cream (Retin-A® ; Janssen-Cilag). METHODS: Seventy-seven men with facial acne scored 2-3 according to Investigator's Global Assessment (IGA) were randomized to receive placebo cream (n = 15), or CB-03-01 1% cream (n = 30), or tretinoin 0·05% cream (n = 32) once a day at bedtime for 8 weeks. Clinical efficacy was evaluated every 2 weeks including total lesion count (TLC), inflammatory lesion count (ILC), acne severity index (ASI) and IGA. Safety assessment included local irritancy score, laboratory tests, physical examination, vital signs and recording of adverse events. RESULTS: CB-03-01 1% cream was very well tolerated, and was significantly better than placebo regarding TLC (P = 0·0017), ILC (P = 0·0134) and ASI (P = 0·0090), and also clinically more effective than comparator. The product also induced a faster attainment of 50% improvement in all the above parameters. CONCLUSIONS: This pilot study supports the rationale for the use of topical antiandrogens in the treatment of acne vulgaris. CB-03-01 1% cream seems to fit with the profile of an ideal antiandrogen for topical use.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2133.2011.10332.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 11

  1. Simpson, 2004, Rook’s Textbook of Dermatology, 3, 43.1
  2. Thiboutot, 2003, Update and future of hormonal therapy in acne, Dermatology, 206, 57, 10.1159/000067823 · DOI · Paper page
  3. Chen, 1995, Local and systemic reduction by topical finasteride or flutamide of hamster flank organ size and enzyme activity, J Invest Dermatol, 105, 678, 10.1111/1523-1747.ep12324390 · DOI
  4. Celasco, 2004, Biological profile of cortexolone 17α-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist, Arzneimittelforschung, 54, 881
  5. Burke, 1984, The assessment of acne vulgaris - the Leeds technique, Br J Dermatol, 111, 83, 10.1111/j.1365-2133.1984.tb04020.x · DOI · Paper page
  6. Tucker, 1984, Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris, Br J Dermatol, 110, 487, 10.1111/j.1365-2133.1984.tb04664.x · DOI
  7. Center for Drug Evaluation and Research, 2005, Guidance for Industry. Acne Vulgaris: Developing Drugs for Treatment
  8. Thieliz, 2010, Topical retinoids in acne - an evidence-based overview, J Dtsch Dermatol Ges, 8, S15
  9. Berger, 2007, A double-blinded, randomized, vehicle-controlled, multicenter, parallel-group study to assess the safety and efficacy of tretinoin gel microsphere 0·04% in the treatment of acne vulgaris in adults, Cutis, 80, 152
  10. Nighland, 2008, Tretinoin microsphere gel in facial acne vulgaris: a meta-analysis, J Drugs Dermatol, 8, S2
  11. Webster, 2009, A combined analysis of 2 randomized clinical studies of tretinoin gel 0·05% for the treatment of acne, Cutis, 83, 146

Cited by

See all 66

Metadata

Authors
Trifu, V., Tiplica, G.-S., Naumescu, E., Zalupca, L., Moro, L., & Celasco, G.
Venue
British Journal of Dermatology
Published
2011-06-02
Volume
165
Issue
1
Pages
177-183
ISSN
0007-0963 (ISSN-L)
OpenAlex
W2165062882
Cited by
66
References
0
FWCI
4.07
Type
journal article
Language
en
Open access
closed
Licence
doi.wiley.com/10.1002/tdm_license_1 (tdm, 1552 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cortexolone 17α-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0·05% cream: Cortexolone 17α-propionate in acne vulgaris. https://app.cochat.ai/papers/10.1111/j.1365-2133.2011.10332.x
The paper
Trifu, V., Tiplica, G.-S., Naumescu, E., Zalupca, L., Moro, L., & Celasco, G. (2011). Cortexolone 17α-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0·05% cream: Cortexolone 17α-propionate in acne vulgaris. British Journal of Dermatology. https://doi.org/10.1111/j.1365-2133.2011.10332.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.